Ruxolitinib was developed for the treatment of PV and intermediate- and high-risk primary MF including primary MF, post-PV MF and post-essential thrombocythemia MF, where inappropriate activation of JAK2 underlies disease pathogenesis [90]. The gene discussed is JAK2; the disease is acquired polycythemia vera.